brain/
← all mechanisms
med-high convictionactive · updated 2026-09-23T00:00:00.000Z

GLP-1 demand surge → four-layer manufacturing bottleneck → Bachem / Stevanato / West Pharma / Ypsomed

GLP-1 injectable drugs require four specialized manufacturing inputs (peptide API, primary containers, elastomeric components, auto-injector devices) — each layer has a small number of qualified suppliers; the ramp from ~12% of US adults on GLP-1 to the projected $200B market by 2030 creates multi-year capacity demand across all four layers simultaneously.

The chain
1
GLP-1 drug adoption reaches 32M US users as of late 2025 (~1 in 8 US adults); global market $87–101B in 2026, J.P. Morgan projects $200B by 2030. Novo Nordisk and Eli Lilly are scaling toward hundreds of millions of injectable doses annually. Near-term catalyst: FDA 503B compounding ban comment period closes June 29, 2026 — permanently blocks large-scale compounding of semaglutide, tirzepatide, and liraglutide, routing ~10-20% of currently-compounded supply back to branded supply chains.
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "GLP-1 drugs... have reached ~32 million US users as of late 2025 (~1 in 8 US adults). Shortages officially resolved (semaglutide Feb 2025; tirzepatide confirmed resolved by mid-2025)... The FDA is now moving to permanently block large-scale 503B compounding of all three main GLP-1 APIs, removing the compounding safety valve and forcing demand entirely onto branded supply chains."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "J.P. Morgan estimates $200 billion [GLP-1 market] by 2030... Lilly's Q3 2025 GLP-1 sales alone hitting $10 billion (52% of quarterly revenue)."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Compounding ban removes ~10-20% of market supply over the next 12 months, driving demand back to branded supply chains during a period when new capacity is still ramping. This is a near-term bullish catalyst for every tier of the supply chain."
**New dated demand catalyst (2026-06-11).** From 2026-06-11-autoresearch-healthcare-glp1-medicare-biosecure-pbm-june2026: CMS confirmed eligible Medicare beneficiaries get **$50/month GLP-1 access under the BALANCE / Medicare GLP-1 Bridge demonstration beginning July 1, 2026** (through Dec 31, 2027) — first-ever Medicare obesity coverage, "expected to significantly increase demand." Volume runs straight into the fill-finish bottleneck ("the world will need more sterile products than manufacturers have or can build capacity for" — McKinsey). WST GLP-1 exposure quantified: elastomer 10% + West Vantage 8% = **~18% of Q1'26 revenue**; STVN Latina PFS / EZ-fill cartridges reach commercial production early 2027. Device/fill-finish suppliers are paid **per-unit**, so the price cut + volume surge is net-positive (volume-levered, price-agnostic). **This is a near-term (July 1) dated catalyst on top of the June 29 503B compounding-ban close — both bullish for STVN/WST.**
From 2026-04-30-earnings-lly-q1-fy2026: LLY Q1 2026 revenue +56% YoY to $11.3B; FY guidance raised to $82–85B. Mounjaro+Zepbound ~$36B run-rate 2025. — **primary earnings confirmation of GLP-1 demand trajectory**.
**(2026-07-29) Bridge now live — corroboration.** From 2026-07-29-autoresearch-thin-vertical-scan-glp1-bridge-financials: the Medicare GLP-1 Bridge (CMS Section 402 demonstration, **$50/month flat co-pay, outside the Part D risk corridor**) **began July 1, 2026** — re-confirming the dated demand catalyst already ingested (06-11/06-15/06-16). Next read on whether the demand surge outruns fill-finish supply is **LLY Q2 (08-05)** on GLP-1 allocation/capacity. (Low-novelty for this mechanism — already well-documented; folded as reinforcement.)
**503B catalyst sharpened (2026-06-15).** From 2026-06-15-autoresearch-glp1-medicare-bridge-503b-ban-wst-injectable-demand: the FDA proposed (Apr 30, 2026) to exclude semaglutide/tirzepatide/liraglutide from the **503B bulks list**; Makary's rationale is "no clear clinical need" now that shortages are resolved. **Important nuance: June 29 is the *comment-close*, NOT the ban** — the *final determination* (timing unset) is the real gate, so a slow or litigated finalization defers the branded-volume pull. This targets 503B outsourcing facilities specifically (the second of the two legal industrial-compounding pathways). Catalyst date is real but soft; the hard catalyst is the final rule.
gary-millerchip in 2026-05-28-earnings-cost-q3-fy2026 (consumer-channel pharmacy corroboration — GLP-1 driving Costco market share gains at pharmacy level): "Pharmacy led the way and saw significant market share gains in the quarter. In addition... factors... include increased GLP-1 demand, and inclusion of Wegovy and Ozempic in our Member Prescription Program." — independent consumer-channel confirmation that GLP-1 demand is large enough to move pharmacy market-share metrics at a warehouse retailer with 82.9M paid members. Costco adding Wegovy/Ozempic to the Member Prescription Program confirms institutional-scale demand pull at the distribution layer.
**List-price-cut corroboration (2026-06-16).** From 2026-06-16-autoresearch-bucket-healthcare-glp1-pricing-biotech-rotation: under MFN/TrumpRx pressure, Lilly and Novo agreed to cut GLP-1 list prices to **~$149–$350/month** (from $1,000+), while national GLP-1 spend (>$71.7B, ~14% of all US Rx) keeps climbing and the Medicare Bridge expands the pool. This **sharpens the device-vs-manufacturer split**: cheaper per-unit price + Medicare/cash-access volume is a margin event for *LLY/NVO* but a volume event for the *price-agnostic consumable/device suppliers* (WST/STVN paid per-unit) — the picks-and-shovels leg strengthens *relative to* the drug manufacturers on the volume thesis. (Counter-current: some commercial plans, e.g. BCBS Massachusetts, are dropping weight-loss GLP-1 coverage on premium pressure.)
**(2026-08-06) Bridge magnitude REFINED DOWN — the biggest correction on this step.** From 2026-08-06-autoresearch-medicare-glp1-bridge-uptake-and-pen-fill-finish-constraint: **"up to 3.8 million beneficiaries could meet all eligibility criteria"** — because enrollees must be 65+/disabled with BMI ≥35 (or 27–35 with comorbidities) and are **excluded** if they have type 2 diabetes, moderate-to-severe sleep apnea, or MASH. Those carve-outs remove exactly the comorbid population most likely already on a GLP-1. **⚠ Attribution corrected 2026-08-31:** 3.8M is **KFF 2023 claims**, not CMS. CMS has not published an eligible-headcount. From 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge ([KFF 2026-06-29](https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-met-the-eligibility-criteria-in-2023-for-the-medicare-glp-1-bridge/)). **Contrast with management**: dave-ricks in 2026-08-05-earnings-lly-q2-fy2026: *"The Medicare GLP-1 Bridge Program launched on July 1, granting **20 million eligible Americans** insurance coverage… With this expansion, 35% more people now have coverage."* The two are different denominators (Lilly coverage-expansion vs KFF Bridge-eligible after Part D exclusions) and they differ **~5x**. Any volume model built on 20M overstates the Bridge-eligible pool. See **Contradictions / tensions**.
**(2026-08-31) Bridge scripts still none-found.** Same clip: no CMS utilization table, no Lilly 8-K script count, no IQVIA Bridge-tagged print. Foundayo mix stays on the **call, not the 8-K**: ~1-in-4 **new starts** oral vs ~80% of **people getting treatment** injectable — different bases. Do not flatten WST/STVN hardware marks onto LLY.
**(2026-08-06) The Bridge is high-friction by design, which caps the uptake *slope*.** Same source: prescribers must submit the prescription *and* the prior-authorization request **"directly to Bridge's central processor"** rather than through Part D, with processing "up to several days"; the **$50 copay is flat regardless of income with no low-income-subsidy exception**, and **does not count toward deductibles or out-of-pocket maximums**. CBO put potential annual taxpayer cost above **$30 billion** if all eligible enrolled — which is itself an argument the friction is intended to hold.
**(2026-08-06) No observed uptake data exists yet.** Same source: **"CMS has not yet released real-world enrollment numbers"** as of 2026-08-01, five weeks in. Every claim about the Bridge's realized volume effect is currently a forecast, not an observation. First hard read: a CMS release, or LLY/NVO Q3 commentary.
**(2026-08-05) LLY Q2 first-party corroboration of the demand trajectory.** From 2026-08-05-earnings-lly-q2-fy2026: revenue **+48% YoY**; MOUNJARO + ZEPBOUND **$14.9B in the quarter**; US obesity prescriptions **+78% YoY** with Lilly at ~60% of total and ~70% of injectable scripts; FY guidance raised to **$85–87B revenue / $35.50–36.50 EPS**. lucas-montarce: *"We now expect full-year revenue to be between $85 billion and $87 billion."*
**(2026-08-05) The price-vs-volume trade, stated by the CFO.** lucas-montarce in 2026-08-05-earnings-lly-q2-fy2026: *"U.S. price declined by 3%, driven by ZEPBOUND and MOUNJARO"*, and on CVS formulary access — *"will drive basically...price to actually go down...we are going to more than offset that with volume growth."* This is the **per-unit-paid supplier thesis restated by the drug maker itself**: price down + volume up is a margin event for LLY and a pure volume event for WST/STVN/Ypsomed.
**(2026-08-05) Mix, first-party.** ilya-yuffa in 2026-08-05-earnings-lly-q2-fy2026: *"around 80% of people that are getting treatment are injectable"* and, on Bridge patients, *"60%-70% being new people that are coming in that have not had access before."* The installed base stays overwhelmingly injectable; the Bridge is largely **incremental**, not switching.
**(2026-08-05) Manufacturing build-out, first-party.** dave-ricks in 2026-08-05-earnings-lly-q2-fy2026: *"We continued our manufacturing build-out and opened our first dedicated genetic medicine manufacturing facility in Lebanon, Indiana. We also produced the first batch of commercial material at our new manufacturing site in Limerick, Ireland."* patrik-jonsson on ex-US supply: *"There will be no gating of launches either."*
**(2026-08-28) 503B is still a proposal — closing, not reopening; no final fetched.** From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware: [91 FR 23431 (1 May 2026)](https://www.govinfo.gov/content/pkg/FR-2026-05-01/html/2026-08552.htm) proposes **not** to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. Original comment deadline **June 30, 2026**. Comment window later extended to **July 30, 2026** — fetched [FR Doc. 2026-12937](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12937.pdf) (Docket FDA-2018-N-3240). The extension notice says comments will inform FDA’s **final determination**. **No final rule fetched. Do not invent a final.** This sharpens the 2026-06-15 nuance (June 29/30 was comment-close, not the ban) and does **not** reopen the compounding valve.
2
Injectable GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) require **peptide API via solid-phase peptide synthesis (SPPS)** — a specialized manufacturing step requiring large-capacity reactors, purification, and freeze-drying infrastructure that cannot be repurposed from standard pharma. As Novo and Lilly scale, they pull on a small number of validated peptide CDMOs → **Bachem (BANB.SW)** is the world's largest pure-play peptide API CDMO and the direct beneficiary.
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Bachem (SIX: BANB) is the world's largest pure-play peptide API CDMO and the clearest direct beneficiary. FY2025 revenue: CHF 695.1 million (+14.8% YoY; +19.2% in local currencies). H1 2025: CHF 313M (+30.2% vs H1 2024); EBITDA margin 29.1% (up from 23.1%). 2026 target: >CHF 1 billion revenue, >30% EBITDA margin — a 65%+ two-year revenue growth."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Building K (new large-scale SPPS facility): Phase 1 inspected by Swiss Swissmedic at end-2025; commercial production ramping in 2026. Phase 2 still under construction. Building K is the key enabler for the 2026 revenue target."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Peptide API market volume projected to grow from 265 metric tonnes (2025) to 855 MT by 2031 at 21.72% CAGR — volume growth driven by manufacturing scale, not just new drug approvals."
3
Every injectable GLP-1 dose requires a **primary container** (prefilled syringe, vial, or cartridge). Novo Nordisk acquired Catalent's three fill-finish sites (Anagni, Bloomington, Brussels) for $11B — making them captive to Novo and redirecting Eli Lilly and other GLP-1 developers to third-party suppliers → **Stevanato Group (STVN)** absorbs displaced fill-finish demand; GLP-1 revenue grew >50% in 2025 and Nexa prefilled syringes are STVN's fastest-growing product.
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "GLP-1 revenue grew >50% in 2025 vs 2024; GLP-1 = ~19-20% of total 2025 revenue. Fastest-growing product: Nexa prefilled syringes, driven primarily by GLP-1. Customer base for high-value prefilled syringes grew >40% in 2025. 2026 GLP-1 growth guidance: 'mid-teens' percentage."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Novo Holdings acquired Catalent for $16.5 billion (completed December 2024); Novo Nordisk then acquired three Catalent fill-finish sites from Novo Holdings for $11 billion. These three sites are now captive to Novo Nordisk. Eli Lilly CEO publicly complained this could damage competitors' access to fill-finish capacity. Lilly and other GLP-1 developers who cannot use Novo's captured Catalent sites must go elsewhere — i.e., to Stevanato, Lonza, and other independents."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "CapEx 2025: €294.9M (89% deployed for growth), with Fishers, Indiana plant targeting commercial activities by end-2026 / early 2027."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Management projects injectable GLP-1s will remain ~70% of total GLP-1 volume even as oral pills grow."
**(2026-08-28) Q2 FY2026 first-party print — attach, no new chain.** From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware: revenue **€302.0M +8%**; HVS **€135.9M +16%**, **45%** of sales; diluted EPS **€0.08** / adj **€0.14**. FY guide **narrowed** to **€1.260–€1.280B** (Balda sale €12.2M one-time; ~€30M FY revenue out). Fishers: first EZ-fill vial PQ done; full ramp **end-2028**. Latina RTU 400 commercial **2027**. Demand “strong and robust.” NYSE:STVN confirmed.
**(2026-08-28) GLP-1 22–23% is slides + Franco, not 6-K highlights.** Same source: do not promote that mix into the press-release fact set. Contested biologics split left open: slides “Biologics that grew 30% yoy” vs Franco Q&A “6% of growth in biologics.”
4
Every injectable vial and prefilled syringe requires **elastomeric components** (stoppers, seals, plungers) — consumables with a one-per-dose relationship to volume → **West Pharmaceutical Services (WST)** is the primary supplier via its High-Value Products (HVP) line; GLP-1 = 17% of FY2025 net sales, +50% YoY. Oral GLP-1 is additive not cannibalistic: management confirmed "8 of 10 oral GLP-1 patients are new to the market."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "GLP-1 represented 17% of net sales in full-year 2025; grew ~50% YoY. GLP-1 elastomers were 10% of total revenues in Q4 2025; GLP-1 contract manufacturing was 7% of Q4 2025 revenues."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Q1 2026: revenues grew 15% organically, led by HVP components with double-digit growth in GLP-1 and non-GLP-1 products. Full-year 2026 guidance: $3.295B–$3.350B revenues, organic growth 5-7%, HVP components growing high-single-digit to low-double-digit organically. GLP-1 alone forecast to contribute ~+1 percentage point to organic growth."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "'Eight of ten patients using oral GLP-1s are new to the market' — oral pills are expanding total GLP-1 user population, not cannibalizing injectables, which protects WST's elastomer volume."
**Step-4 hardening (2026-06-15).** From 2026-06-15-autoresearch-glp1-medicare-bridge-503b-ban-wst-injectable-demand: West raised FY2026 guidance to **$3.295–3.350B net sales / $8.40–8.75 adj-EPS** on ~15% Q1'26 organic growth; **GLP-1 = ~18% of net sales** (~10% elastomer + ~8% West Vantage). The load-bearing datapoint *against* the oral-substitution bear case: **HVP Delivery Devices net sales +29.0% YoY in Q1'26**, and West announced a **new ~165,000-sq-ft injectable-component facility (late March 2026)** — capacity being added *even as* oral Wegovy launched Jan 2026. West delivers >41B components/devices/yr across 26 facilities. The realized data says additive-not-substitutive **so far**; orforglipron's commercial ramp is the per-quarter recheck variable.
**Price-cut sharpens the consumable-over-manufacturer split (2026-06-18).** From 2026-06-18-autoresearch-bucket-healthcare-cdmo-reshoring-glp1-pricing: the TrumpRx deal cuts GLP-1 **list prices up to 74%**, with cash-pay starting ~$350/mo gliding to **$250 over two years** and a **Medicare Part D $50-copay bridge demo beginning July 2026**. Lower per-unit price + the Medicare bridge = *higher volume* — which is exactly what matters for West (revenue is per-unit on elastomers/fill-finish, price-agnostic) while it compresses the *manufacturers'* (LLY/NVO) margin. The list-price cut is a tailwind for the consumable suppliers, a headwind for the drug makers — the device/consumable tilt of this chain. **Falsifier to watch:** if the 74% list cut shrinks the total *dollar* pool faster than volume grows (price-vs-volume elasticity), even per-unit suppliers could see the dollar TAM dip — the load-bearing uncertainty.
**(2026-08-28) Q2 FY2026 first-party print — attach, no new chain.** From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware: sales **$872.3M**, +13.8% reported / +12.7% organic; diluted EPS **$2.15** / adj **$2.37**. FY26 **raised** to **$3.345–$3.380B** sales / **$8.85–$9.05** adj EPS (prior on page $3.295–$3.350B / $8.40–$8.75). HVP Components **$424.1M +18.4%** organic; HVP Delivery Devices **$131.2M +29.2%** organic; West Vantage **$149.7M +0.8%** organic. Green (IR): HVP Components on biologics, Annex 1, ongoing growth in GLP-1 elastomers — qualitative only on the IR release.
**(2026-08-28) 18% GLP-1 mix is DECK-ONLY.** Same source: **10% elastomer + 8% West Vantage = 18% of Q2 net sales**. Do **not** treat 18% as all-elastomer tightness. Official WST transcript was **not** retrieved; Benzinga oral-cannibalization quotes were not filed.
**(2026-08-28) Orals are a live derailer, not a printed mix collapse.** Same source: Foundayo (orforglipron) FDA-approved **1 April 2026**, shipping **6 April** ([Lilly IR](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)). Wegovy pill **3 million prescriptions** since **5 January 2026**; **more than 80% of new Rx new-to-GLP-1** (expanding, not replacing); injectable Wegovy HD also strong ([Novo / PR Newswire](https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html)). **Class-level oral share >30% is not established** — do not treat brand-mix tape as class share. WST/STVN mix is **up, not down**. Injectable **unit volumes still undisclosed**. June honest gap stays open: pricing power vs normalized capacity is still inferred.
5
GLP-1 drugs are delivered via **auto-injector pens** (Ozempic FlexPen, Wegovy pen, Zepbound pen) — high-precision molded devices not interchangeable with commodity parts → **Ypsomed (YPSN.SW)** holds a Novo-funded supply agreement for YpsoMate 1mL autoinjectors; Novo funded "a significant part of the investment" for new Ypsomed facilities in China and Germany; commercial deliveries began 2025.
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "Signed a supply agreement with Novo Nordisk to produce large quantities of YpsoMate 1mL autoinjectors for GLP-1 drugs. Novo Nordisk funded 'a significant part of the investment' for Ypsomed's new production infrastructure (new facilities in China and Germany). Commercial deliveries to Novo began in 2025."
From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries: "GLP-1 Autoinjector & Pen Injector market projected at 15.6% CAGR 2026-2035."
**(2026-08-06) The Bridge formulary routes volume *specifically into this layer*.** From 2026-08-06-autoresearch-medicare-glp1-bridge-uptake-and-pen-fill-finish-constraint: the Bridge covers semaglutide (Wegovy) injection **and** tablet, orforglipron (Foundayo) at all strengths, and tirzepatide (Zepbound) **as KwikPen only** — not vials, not the single-dose autoinjector. Separately: *"vials are more consistently available than KwikPens for the higher doses because Lilly's vial filling capacity expanded faster than autoinjector capacity"*, and **the KwikPen device is manufactured by ypsomed (Switzerland)** and shipped to Indianapolis for filling and final assembly. So CMS has written a formulary that points newly-covered tirzepatide volume at the **pen/autoinjector** presentation, which is the documented constrained one — a within-chain reallocation from step 3 (PFS/Stevanato) toward step 5 (pens/Ypsomed).
**(2026-08-06) Scale reference**: a Lilly investor presentation in early 2026 put US Zepbound dispensing at roughly **3.8 million pens per month**, up from 800,000 in mid-2023. Same source.
**(2026-08-06) ⚠ The offsetting fact — do not skip it.** Lilly has introduced a **multi-dose KwikPen** (one device = a one-month supply), explicitly designed to ease device supply constraints. That **reduces pens-per-patient-month**, cutting device demand per script. More covered patients raises pen demand; fewer pens per patient lowers it, and **no source nets these out**. Until they are netted, "Bridge → pen fill-finish squeeze" is an **asserted** step, not a confirmed one.
Contradictions / tensions
  • **Oral GLP-1 risk**: orforglipron (Foundayo) is a non-peptide small molecule — no SPPS, no prefilled syringe, no elastomeric stopper, no auto-injector. If oral share exceeds 30% of new prescriptions by 2027, the volume growth rate at Bachem/STVN/WST/Ypsomed slows even as GLP-1 total market grows. Management guidance (WST: oral is additive; STVN: 70% injectable durability) currently rejects the cannibalization thesis, but this remains the primary falsifier.
  • **FDA shortage resolution**: the official shortage listing ended (semaglutide Feb 2025; tirzepatide mid-2025). The acute supply crunch that created pricing power has partially normalized. The multi-year capacity demand argument remains valid — but the "emergency premium" may have already been arbitraged away.
  • **Bachem Building K execution risk**: the 2026 >CHF 1B target is contingent on Building K Phase 2 coming online. A delay pushes the revenue target and disappoints the market.
  • **(2026-08-06) 20M vs 3.8M — the eligible-population contradiction.** dave-ricks on the Q2 call cited *"20 million eligible Americans"*; **"up to 3.8 million"** who "could meet all eligibility criteria" was ingested via 2026-08-06-autoresearch-medicare-glp1-bridge-uptake-and-pen-fill-finish-constraint, and this wiki's glp1-substitution-to-bariatric-surgery-decline step 2 already carried the 3.8M figure. **⚠ Attribution corrected 2026-08-31:** 3.8M is **KFF 2023 claims**, not CMS. CMS pages retrieved for 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge publish **no headcount**; Klomp "single-digit millions" is via KFF, not independently retrieved. **Resolution recorded, not reconciled away:** both numbers are attributable and measure different things (Lilly coverage-expansion vs KFF Bridge-eligible after T2D/OSA/MASH/prior-GLP-1 exclusions). **The wiki's operative number stays 3.8M** — it is KFF's, it is the narrower Bridge-eligible print, and it was here first. Ricks's 20M is retained as *management's framing*, flagged as a denominator substitution that makes the catalyst look ~5x larger than it is. Actual Bridge scripts remain **none-found**.
  • **(2026-08-06) The multi-dose KwikPen is a genuine counter-current to the device leg** (fewer pens per patient-month), unmodelled. See Implications.
  • **(2026-08-28) WST 18% mix is not all elastomer.** Deck: 10% elastomer + 8% West Vantage. West Vantage printed +0.8% organic. IR names GLP-1 elastomers qualitatively only. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • **(2026-08-28) STVN GLP-1 22–23% is slides + Franco, not 6-K highlights.** Same source.
  • **(2026-08-28) STVN biologics split left open.** Slides “Biologics that grew 30% yoy” vs Franco Q&A “6% of growth in biologics.” Same source.
  • **(2026-08-28) Oral derailer is live; class share is not.** Foundayo shipping; Wegovy pill expanding on brand tape (>80% new-to-GLP-1). That is **not** class-level oral share >30%. Mix at WST/STVN is up. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • **(2026-08-28) June honest gap stays open.** Q2 mix-up does not show that WST/STVN command a capacity-constraint pricing premium versus post-shortage normalized capacity. Injectable unit volumes still undisclosed. Still inferred. Same source.
Implications
  • **STVN** (NYSE, liquid) — highest conviction; largest disclosed GLP-1 revenue share, Catalent structural demand redirect, US manufacturing in build-out phase
  • **WST** (NYSE, liquid) — high conviction; consumable model, 17% of net sales documented, oral GLP-1 framed as additive
  • **BANB.SW** (SIX, no liquid US ADR) — highest conviction if accessible; dominant market position, Building K ramp provides multi-year visibility; thin US execution
  • **YPSN.SW** (SIX, no liquid US ADR) — medium-high conviction; Novo-funded capacity provides revenue visibility but single-customer concentration risk
Companies
Bachem Holding AG (BANB.SW)Stevanato Group (NYSE: STVN)West Pharmaceutical Services (NYSE: WST)Ypsomed AG (SWX: YPSN)
Concepts
S-Curve Evaluation Lens
Open questions
Is the GLP-1 demand surge creating an injectable supply-chain bottleneck that benefits Bachem, Stevanato, and West Pharma?